A Clinical Study of PLX-200 for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis
Latest Information Update: 22 Jan 2020
At a glance
- Drugs PLX 200 (Primary)
- Indications Neuronal ceroid lipofuscinosis
- Focus Adverse reactions
- Sponsors Polaryx Therapeutics
Most Recent Events
- 20 Jan 2020 According to a Polaryx Therapeutics media release, the company has received an Investigational New Drug Application (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) patients with PLX-200.
- 30 Dec 2019 New trial record
- 22 Dec 2019 According to a Polaryx Therapeutics media release, the Company has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for the treatment of patients with Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL).The company will start this trial as soon as possible.